Agenda

Welcome Reception

Breakfast & Registration

Welcome & introduction
Gareth Morgan & Ola Landgren 

Session 1A: Genomics and epigenomics 2026
Chairs: Gareth Morgan and Leif Bergsagel

Are NSD2 or MAF targets for therapy

• Mechanistic basis of NSD2 as an oncogene: Yubao Wang
• Apoptotic profiling of t(4:14) MM: Lawrence Boise
• Distinct epigenetic programs of high-risk MM subtypes create targetable dependencies: Benjamin Barwick

Panel Discussion     

Session 1B: Can we identify new prognostic factors and targets for therapy?
Chairs: Gareth Morgan and Leif Bergsagel

• Genetics and epigenetics of early myeloma: Mehmet Samur
• Structural variation in HR: Patrick Blaney
• Targeting structural variation by their detailed characterization: Brian Walker
• Deciphering the biology of bone marrow-independent disease to identify therapeutic vulnerabilities:
  Niels Weinhold

Panel Discussion             

Break

Session 2: Targeting resistance mechanisms and HR biology
Chairs: Marta Chesi &  Larry Boise 

• Epigenetic and epitranscriptomic targets in MM: Felipe Prosper
• Epi drivers and drug resistance: Gareth Morgan
• Targeting super enhancers: Leif Bergsagel
• How to overcome resistance mechanisms to bispecific antibodies in MM: Nizar Bahlis
• Targeting p300: Charlotte Pawlyn

Panel discussion

Lunch

Session 3: Using biological models and single cell analyses to study drugs
Chairs: Felipe Prosper & Brian Walker

• Modelling resistance to t-cell therapies: Marta Chesi
• Using mouse models to find new targets: Marta Larrayoz
• A novel, genetically driven vulnerability to mitosis targeting in multiple myeloma: Sarah Gooding
• CSF-1R inhibition & lenalidomide synergy in myeloma post ASCT: Simone Minnie
  Immune landscape–driven target discovery in myeloma: Manoj Bhasin

Panel discussion: Future strategies for myeloma management

Plenary Lecture
Location, Location, Location; expanding our understanding of the TME in myeloma: Robert Orlowski
Chairs:  Ola Landgren & Gareth Morgan

Panel discussion

Break

Session 4: Integration of Clinical and Translational Research with the MMRF
Chairs: George Mulligan & Hearn Cho

• Molecular correlates of dara use in RRMM: Robert Orlowski
• MM immune atlas: insights on NDMM and RRMM: Chuck Acharya
• Horizon 2: an adaptive platform trial for high-risk NDMM: Ben Derman

Panel Discussion

Closing Remarks for Day 1

Attendee Dinner

Welcome and Introductions Day 2

Session 5: Early use of immunotherapy in multiple myeloma
Chairs: Faith Davies & Paola Neri

• Use of cell-free DNA (cfDNA) to monitor antigen escape and detect early relapsing disease: Paola Neri
• Anito-cel: Ciara Freeman
• High-risk in the context TecDara: Mark Raab
• The role of abbreviated bispecific immuno-consolidation in newly diagnosed myeloma; IMMUNOPLANT Study: Dickran Kazandjian
• Cartitude-4: update: Yi Lin
• Isatuximab combinations: Dickran Kazandjian
• Alpha Emitter Targeted Therapy: Damian Green

Panel Discussion

Session 6: Artificial intelligence in multiple myeloma
Chairs: Ciara Freeman & Leo Rasche                          

• The benefit of AI in multiple myeloma: Ciara Freeman
• AI in patient management: Ola Landgren

Panel discussion: Optimizing therapy choices at relapse

Break

Session 7: Optimizing T-Cell Engaging therapy
Part 1: CAR-T Management
Chairs: Adam Cohen & TBC

• Managing neurotox and ALC expansion: Leo Rasche
• The role of arlocel: Marc Raab
• STEM study: Adam Cohen
• In vivo CAR-T designs: Yi Lin
• The role of anti CD19 binders in CAR-T constructs: Nina Shah

Panel discussion: Optimizing the use of CAR-T in the clinic

Part 2: Bispecifics, ADCs, and Allogeneic CAR-T therapies in MM
Chairs: Yi Lin & Malin Hutlcrantz

• Tal/Tec and their management: Malin Hultcrantz
• Linvoseltamab; Hans Lee
• Elranatamab: Ola Landgren
• Cevostamab:  Adam Cohen
• Anito-cel: Gareth Morgan
• CB-011: Binod Dhakal
• ABBV 383: Shaji Kumar
• Trispecifics: Faith Davies
• AbbVie’s multiple myeloma vision: Annelore Cortoos

Panel discussion: Optimizing the use of Bispecifics  & ADCs in the clinic 

Summary & closing remarks of iwMyeloma 2026
Gareth Morgan & Ola Landgren